Q3 FY26 · Ended Sep 26, 2026 · View SEC filing
Net income topped pre-tax income on a tax reversal
A reversed tax reserve from the primate supplier purchase supplied about half of net income, so EPS says little about the labs.
For investorsWhat the margin depends on once one-time items pass
For foundersPruning a portfolio to raise the margin of what remains
Selling, administrative and amortization costs fell far faster than revenue, as sold businesses and one-off items left the cost base.
Manufacturing brings 18.2% of revenue but 23.0% of segment profit, helped by leaving the lower-margin CDMO business.
Last fiscal year closed with a net loss, yet the operations produced cash, helped by lighter capital spending.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Charles River Laboratories from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.